Tech Company M&A Transactions
OncoImmune Acquisition
On 11/23/2020, OncoImmune was acquired by Merck. Merck said the transaction price was $425 million.
Transaction Overview
Company Name
Acquired By
Announced On
11/23/2020
Transaction Type
M&A
Amount
$425,000,000
M&A Terms
Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9430 Key West Ave. 113
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Overview
Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Pan Zheng
Chief Operating Officer
Martin Devenport
Founder
Kun-Liang Guan
Founder
Ming You
President
Yang Liu
VP - Operations
Raymond Touomou
VP - Regulatory Affairs
Weng Tao
Browse more venture capital transactions:
Prev: 11/23/2020: OurCrowd venture capital transaction
Next: 11/23/2020: Observable venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs